Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Cherney, PhD, MD
University of Toronto
Principal Investigator - Ian de Boer, MD, MS
University of Washington
Principal Investigator - Irl Hirsch, MD
University of Washington
Principal Investigator - Jessica Kendrick, MD
University of Colorado Anschutz Medical Campus and Children's Hospital Colorado
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Toronto General Hospital, University Health Network
Toronto, Ontario, Canada
David Cherney, MD CM PhDRecruiting
- Recruiting
- University of Washington
Seattle, Washington, United States
Irl Hirsch, MDRecruiting - Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Apr 2024
- Primary completion
- 30 Jun 2027
- Completion
- 31 Dec 2027
- Last update posted
- 2 Jun 2026
- Registered enrollment
- 60
- Registry id
- NCT05822609
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.